ArticleFrontiers in immunology2025
Synergistic hyperinflammation in IgA vasculitis complicated by varicella-induced HLH: a case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Varicella-zoster virus (VZV)-induced hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal complication, particularly in immunocompromised hosts. We present an 11-year-old boy with IgA vasculitis who developed severe VZV-HLH complicated by disseminated intravascular coagulation (DIC), acute liver failure and persistent lymphocytopenia. A multimodal therapeutic approach that combining high-dose acyclovir, intravenous immunoglobulin (IVIG), therapeutic plasma exchange (TPE), reduced-dose etoposide (75 mg/m²), and dexamethasone achieved rapid disease remission. This case demonstrates synergistic risk of HLH when VZV infection overlaps with IgA vasculitis, likely via compounded immune dysregulation. This case suggests that when varicella zoster virus infection overlaps with IgA vasculitis, it may synergistically increase the risk of HLH through aggravated immune dysregulation. In infection-triggered HLH, step-wise immunomodulatory therapy has a key role. What's more, lymphocytopenia may be used as a biomarker to assess disease severity and recovery, and this finding emphasizes the need for long-term immune monitoring. This case provides valuable insights into the pathogenesis and management of VZV related HLH in rheumatic and immune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.